SavedAdd your journal

Journals / Damar Cerrahi Dergisi / 2018 / Cilt: 27 - Sayı: 3

Protective effect of cilostazol and rosuvastatin on acute kidney injury-induced lung injury using TNF-a and HIF-1a immunoreactivities

TNF-a and HIF-1a immünreaktivitesi ile silostazol ve rosuvastatinin akut böbrek hasarı ile oluşturulan akciğer hasarı üzerine koruyucu etkileri

Ali GÜRBÜZ
Börteçin EYGİ
Habib ÇAKIR
Köksal DÖNMEZ
Şahin İŞCAN
Fatmagül KUŞKU ÇABUK
İsmail YÜREKLİ
Pages
130–136
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tumor necrosis factor-a (TNF-a) and hypoxiainducedfactor-1a (HIF-1a) antibodies were used for immunohistochemical examinations of lung tissues cross-sections.Results: TNF-a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly,compared to I/R group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the effects of preoperative cilostazol and rosuvastatin therapy on isolated kidney ischemia/reperfusison (I/R)injury-induced remote lung reperfusion injury in an experimental model.Materials and methods: A total of 35 female Sprague-Dawley rats were randomly divided into five groups (n=7).
📊
Key Findings & Data:Median laparotomy and a 45-min bilateralkidney ischemia were performed.
💡
Conclusion & Impact:Tumor necrosis factor-a (TNF-a) and hypoxiainducedfactor-1a (HIF-1a) antibodies were used for immunohistochemical examinations of lung tissues cross-sections.Results: TNF-a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly,compared to I/R group (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to investigate the effects of preoperative cilostazol and rosuvastatin therapy on isolated kidney ischemia/reperfusison (I/R)injury-induced remote lung reperfusion injury in an experimental model.Materials and methods: A total of 35 female Sprague-Dawley rats were randomly divided into five groups (n=7). Median laparotomy and a 45-min bilateralkidney ischemia were performed. Oral medications were administered three days before the surgical intervention (20 mg/kg cilostazol, 10 mg/kg rosuvastatin,and 20 mg/kg cilostazol+10 mg/kg rosuvastatin). Lung tissue samples were extracted one day after surgery. Tumor necrosis factor-a (TNF-a) and hypoxiainducedfactor-1a (HIF-1a) antibodies were used for immunohistochemical examinations of lung tissues cross-sections.Results: TNF-a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly,compared to I/R group (p

Özet

Amaç: Bu çalışmada deneysel bir modelde ameliyat öncesi silostazol ve rosuvastatinin izole böbrek iskemi-reperfüzyon (I/R) hasarı sonrasında oluşan akciğer reperfüzyon hasarı üzerine etkileri araştırıldı. Gereç ve Yöntemler: Toplam 35 adet dişi Sprague-Dawley sıçan rastgele beş gruba ayrıldı (n=7). Medyan laparotomi ve her iki böbreğe 45 dk. iskemi uygulandı. Cerrahi girişimden üç gün öncesinden başlayarak (20 mg/kg silostazol, 10 mg/kg rosuvastatin ve 20 mg/kg silostazol+10 mg/kg rosuvastation) oral tedaviler uygulandı. Cerrahiden bir gün sonra akciğer dokusu örnekleri alındı. Akciğer çapraz kesit dokularının immünhistokimyasal incelemesi için tümör nekroz faktör-a (TNF-a) ve hipoksi ile indüklenmiş faktör-1a (HIF-1a) antikorları kullanıldı. Bulgular: TNF-a immünreaktivitesi I/R+silostazol, I/R+rosuvastatin ve I/R+silostazol+rosuvastatin gruplarında, I/R grubuna kıyasla anlamlı düzeyde azalmış tespit edildi (p

🔖

Cite This Article

GÜRBÜZ, A., EYGİ, B., ÇAKIR, H., DÖNMEZ, K., İŞCAN, Ş., ÇABUK, F. K., YÜREKLİ, İ. (2022). Protective effect of cilostazol and rosuvastatin on acute kidney injury-induced lung injury using TNF-a and HIF-1a immunoreactivities. Damar Cerrahi Dergisi, Cilt: 27 - Sayı: 3, 130–136. https://ajindex.com/articles/486618

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Campanholle G, Landgraf RG, Gonçalves GM, Paiva VN, Martins JO, Wang PH, et al. Lung inflammation is induced by renal ischemia and reperfusion injury as part of the systemic inflammatory syndrome. Inflamm Res 2010;59:861-9.
  2. Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol 2010;21:345-52.
  3. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, et al. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 2007;21:321-30.
  4. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006;189:350-7.
  5. Khandoga A, Enders G, Biberthaler P, Krombach F. Poly(ADP-ribose) polymerase triggers the microvascular mechanisms of hepatic ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2002;283:553-60.
  6. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga CH, Goss CH, et al. Early tumor necrosis factoralpha release from the pulmonary macrophage in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2004;127:1502-8.
  7. Matsuo S, Saiki Y, Adachi O, Kawamoto S, Fukushige S, Horii A, et al. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension. J Thorac Cardiovasc Surg 2015;149:902-9.
  8. Ferreira TS, Lanzetti M, Barroso MV, Rueff-Barroso CR, Benjamim CF, de Brito-Gitirana L, et al. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation 2014;37:1355-65.
  9. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C, Mulligan MS. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 2003;126:482-9.
  10. Awad AS, El Sharif A. Immunomodulatory effects of rosuvastatin on hepatic ischemia/reperfusion induced injury. Immunopharmacol Immunotoxicol 2010;32:555-61.
  11. Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, et al. Cilostazol therapy attenuates monocrotalineinduced pulmonary arterial hypertension in rat model. Circ J 2008;72:825-31.
  12. Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, et al. Early combined treatment with cilostazol and